V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016948 | 160016482 | 1.61 | 90.8 | Adjuvant (A) | 2017-08-01 | 2017-08-03 | Irinotecan + Temozolomide | Y | N | GEMCITABINE | 101428663 |
| 160016951 | 160016483 | 1.6 | 54.2 | Palliative (P) | null | 2018-01-02 | CARBOPLATIN + VINORELBINE | 02 | N | NOT MATCHED | 101793839 |
| 160016953 | 160016484 | 1.77 | 60.3 | Curative (C) | 2016-02-22 | 2016-03-13 | Dinutuximab Beta | 02 | N | NEMO TRIAL | 100054016 |
| 160016955 | 160016485 | 1.22 | 76.5 | Curative (C) | null | 2019-01-01 | EW EuroEwing 2012 Arm A VIDE | null | null | GEMCITABINE | 101863220 |
| 160016959 | 160016486 | 0 | 95.2 | null | 2019-12-03 | 2020-04-23 | Carboplatin + Vinorelbine IV | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 100659204 |
| 160016965 | 160016487 | 1.08 | 29.9 | null | 2017-05-23 | 2017-05-23 | CVP R | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100019609 |
| 160016971 | 160016488 | 0 | 78.2 | Palliative (P) | null | 2019-11-07 | ETOP 13-18 BEAT-meso Trial | 02 | N | NIRAPARIB | 100977599 |
| 160016975 | 160016489 | 1.65 | 58.8 | Palliative (P) | 2019-04-25 | 2019-05-14 | Niraparib | 02 | N | NIRAPARIB | 100761456 |
| 160016978 | 160016490 | null | null | null | 2016-07-13 | 2016-07-26 | NB HRNBL-1 BUMEL MAT | 02 | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 101383967 |
| 160016986 | 160016491 | 0 | 17.8 | Palliative (P) | 2018-09-16 | 2018-09-30 | ETOP 13-18 BEAT-meso Trial | N | N | CARBOPLATIN + FLUOROURACIL | 100200365 |
| 160016988 | 160016492 | 1.81 | 104 | Palliative (P) | 2019-01-23 | 2019-01-26 | VIDE | 02 | N | IFOSFAMIDE | 100910350 |
| 160016990 | 160016493 | 1.62 | 13.3 | Curative (C) | 2021-05-10 | 2021-05-28 | IPILIMUMAB + NIVOLUMAB | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101822042 |
| 160016993 | 160016494 | 1.7 | 121 | 03 | 2017-05-01 | 2017-05-04 | Olaparib | null | null | CREATE TRIAL | 100212183 |
| 160016994 | 160016495 | 1.69 | 75 | Palliative (P) | 2017-10-17 | 2017-10-25 | Niraparib | 02 | N | DACARBAZINE + GEMCITABINE | 101183197 |
| 160016996 | 160016496 | 1.7 | 10 | Palliative (P) | 2020-06-23 | 2020-08-10 | Cyclophosphamide + Etoposide (iv) | 02 | N | OLAPARIB | 100086284 |
| 160017000 | 160016497 | 1.8 | 81.4 | null | 2018-04-03 | 2018-04-04 | IPM | null | null | CYCLOPHOSPHAMIDE | 101514865 |
| 160017009 | 160016498 | 0 | 81 | Curative (C) | 2019-03-05 | 2019-07-30 | null | 02 | null | WT SIOP 2002 01 POST OP CARBO, ETOP | 101316985 |
| 160017011 | 160016499 | 1.85 | 72 | Palliative (P) | 2018-02-17 | 2018-08-13 | FLUOROURACIL + OXALIPLATIN | N | N | IPILIMUMAB + NIVOLUMAB | 100970885 |
| 160017014 | 160016500 | 1.67 | null | null | 2016-05-11 | 2016-05-18 | Niraparib | N | null | NIRAPARIB | 101467040 |
| 160017018 | 160016501 | 0 | 68.4 | Palliative (P) | 2017-11-06 | 2017-12-04 | VAI (Ifos 3g/m2) | 2 | N | NIRAPARIB | 101215625 |
| 160017019 | 160016502 | 0 | 55.1 | Palliative (P) | 2015-12-07 | 2018-03-28 | Azacitidine | 02 | N | IFOSFAMIDE | 100745063 |
| 160017024 | 160016503 | 1.68 | 80 | null | 2017-07-21 | 2017-07-28 | GEMCITABINE | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101513533 |
| 160017026 | 160016504 | 1.6 | 63 | Palliative (P) | 2018-06-11 | 2018-06-30 | Niraparib | 02 | N | NIRAPARIB | 101054812 |
| 160017030 | 160016505 | 1.54 | 57.2 | Palliative (P) | 2017-08-29 | 2017-08-31 | Ifosfamide | 02 | N | TEMOZOLOMIDE | 101823003 |
| 160017031 | 160016506 | 1.64 | 70.3 | null | 2019-08-16 | 2019-08-17 | Cisplatin + Etoposide po | 02 | null | IVA | 100388956 |
| 160017032 | 160016507 | null | null | null | 2018-03-22 | 2018-04-20 | ETOP 13-18 BEAT-meso Trial | 02 | null | DACARBAZINE | 101275146 |
| 160017043 | 160016508 | 0 | 60.2 | Curative (C) | 2016-10-24 | 2016-12-06 | ETOP 13-18 BEAT-meso Trial | 02 | N | RUCAPARIB | 101658857 |
| 160017044 | 160016509 | 0 | 83.5 | null | 2017-05-11 | 2018-01-18 | CISPLATIN + ETOPOSIDE | 02 | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 101125629 |
| 160017045 | 160016510 | 1.6 | 78.1 | null | 2019-07-01 | 2019-10-05 | DACARBAZINE + GEMCITABINE | 02 | null | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 100263234 |
| 160017052 | 160016511 | 1.83 | 57.2 | null | null | 2017-04-11 | Dacarbazine | 02 | null | IVA | 100940818 |
| 160017053 | 160016512 | 1.65 | 85.1 | Adjuvant (A) | 2018-09-14 | 2018-09-18 | REGORAFENIB | 02 | N | GEMCITABINE | 100949152 |
| 160017054 | 160016513 | 1.66 | 74.8 | Adjuvant (A) | 2021-09-29 | 2021-10-10 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | BRIGATINIB | 101068411 |
| 160017062 | 160016514 | 1.78 | 84 | Curative (C) | 2019-05-31 | 2019-06-21 | EW EuroEwing 2012 Arm B IE | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101853493 |
| 160017067 | 160016515 | 1.64 | 89.3 | null | 2020-09-10 | 2020-09-25 | EW Rel rEECur Gemcitabine/Docetaxel + GCSF | 02 | null | TEMOZOLOMIDE | 100157495 |
| 160017076 | 160016516 | 0 | 26.1 | Palliative (P) | 2019-11-06 | 2019-11-06 | EW EuroEwing 2012 Arm A VAI | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101525979 |
| 160017078 | 160016517 | 1.76 | 80 | Adjuvant (A) | 2018-07-28 | 2018-07-31 | IPILIMUMAB + NIVOLUMAB | 02 | null | NOT MATCHED | 101464795 |
| 160017084 | 160016518 | null | null | Palliative (P) | 2017-01-29 | 2017-02-08 | Atezolizumab | N | N | PEMBROLIZUMAB | 100699224 |
| 160017091 | 160016519 | 0 | 141.6 | null | 2018-09-16 | 2018-09-18 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | PEMBROLIZUMAB | 101284569 |
| 160017102 | 160016520 | null | 65.4 | 03 | 2017-11-02 | 2017-11-16 | Dacarbazine | 02 | null | NOT MATCHED | 100353353 |
| 160017106 | 160016521 | 1 | 79.2 | Adjuvant (A) | 2020-10-25 | 2020-11-03 | STS Rhabdo RMS 2005 Vin Cyclo | 01 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100451101 |
| 160017109 | 160016522 | 1.82 | 38 | Palliative (P) | 2017-05-04 | 2017-10-04 | Carboplatin + Vinorelbine IV | 02 | N | STS RHABDO VIT0910 VINC IRINO TEMOZ | 101100354 |
| 160017114 | 160016523 | 1.59 | 13.7 | Adjuvant (A) | 2017-08-27 | 2017-08-28 | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 01 | N | NB HRNBL-1 COJEC IND COURSE C | 101694963 |
| 160017119 | 160016524 | null | null | null | 2020-04-12 | 2020-04-18 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 01 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100674859 |
| 160017128 | 160016526 | 1.42 | 103 | 03 | 2016-11-19 | 2017-02-13 | EW EuroEwing 2012 Arm B IE | N | N | EW EUROEWING 99 : VACTI | 100315424 |
| 160017140 | 160016528 | 1.73 | 77 | 03 | 2020-03-09 | 2020-07-23 | Ifosfamide | 02 | N | ACALABRUTINIB | 100022048 |
| 160017143 | 160016529 | 1.67 | 69.1 | Palliative (P) | null | 2020-07-30 | EOX | 02 | N | ETOPOSIDE | 101237274 |
| 160017144 | 160016530 | 1.56 | 81.6 | null | 2017-08-22 | 2017-08-24 | Ifosfamide | Y | null | ETOP 13-18 BEAT-MESO TRIAL | 101293282 |
| 160017151 | 160016531 | 1.75 | 50 | null | 2016-11-20 | 2016-11-20 | IPM | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101212727 |
| 160017158 | 160016532 | 1.51 | 10.2 | Palliative (P) | 2018-09-10 | 2018-09-11 | CISPLATIN + GEMCITABINE | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101600360 |
| 160017159 | 160016533 | 1.84 | 64 | Palliative (P) | 2020-05-23 | 2020-05-24 | Cyclophosphamide PO +Vinorelbine IV | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101794810 |